2024-03-31-accounts

Report and Accounts 31 March 2024

Research That Saves Lives

leukaemiamyelomaresearchuk.org

Registered charity number 1161622 (England & Wales), SC046106 (Scotland), Leukaemia and Myeloma Research UK Ltd

Company Limited by guarantee Registered number 09481278

Research That Saves Lives

Leukaemia and Myeloma Research UK Ltd Unit 127, North Mersey Business Centre, Woodward Rd, Knowsley Industrial Park, Liverpool, Merseyside, L33 7UY

Tel: [phone]

Web: www.leukaemiamyelomaresearchuk.org Email: [e-mail]

Charity Number 1161622 Company Number 09481278

Follow us on Twitter: https://twitter.com/lmruk_org

Facebook: https://www.facebook.com/leukaemiamyelomaresearchuk.org

Together we can beat cancer Annual Report 2023-24

Table of contents

Charitable Activities............................................................................................. 5 MCB Service......................................................................................................... 9 Donate Clothes to Sammy ................................................................................ 11 Research Priorities.............................................................................................. 12 Accounts .............................................................................................................. 15

https://leukaemiamyelomaresearchuk.org 2

Leukaemia & Myeloma Research UK Ltd wants to prevent people dying from blood cancer regardless of how long it might take.

Founded in 2015, our mission is to prevent people dying from blood cancer through prevention, research and more effective treatment.

Unfortunately, blood cancer affects a large number of someone in the UK is told they have a blood cancer. That’s around 110 people per leukaemia deaths every year,

We are aiming to become the UK’s leading charity in supporting efforts to combat the three major types of blood cancer. The work we do helps fund vital stem cell research, raises awareness of stem cell therapies and helps families protect their children’s future health by storing their cord blood stem cells at the time of birth.

cancers of the blood; they are lymphoma, leukaemia and myeloma.

The blood is made up of three different types of cells:

Red blood cells which carry the oxygen around the body and stop infections

blood to clot

cell therapies

Provide information about blood cancers and treatment options

The course of treatment given will depend on the type of cancer. The most common treatments are chemotherapy, radiotherapy and in some instances, a stem cell transplant.

Protecting the vulnerable by offering qualifying expectant mothers, with a family history of cancer, the opportunity to store their baby’s umbilical cord blood stem cells at the time of birth, in case they are needed in the future to treat that child or another member of the family if they’re a suitable match.

In essence, the Charity wants to eradicate blood cancer once and for all. One of the ways we are aiming to achieve that is through advancing our understanding of stem cells and how we can use them to treat patients with blood cancer, particularly through stem cell transplants. We do this by:

This service is called Model Cell Biobank (MCB).

Actively supporting stem cell research into blood cancers

Raising awareness of stem

Platelets which help the

Stem Cells

In humans, there are two types of stem cells: embryonic stem cells and adult stem cells, which are found in various tissues.

Adult stem cells are the primary focus of the research that the Charity supports. They typically generate the cell types of the tissue in which they reside.

For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow—which is called a hematopoietic stem cell— cannot give rise to the cells of a very different tissue, such as nerve cells in the brain.

Where are stem cells found?

There are four known accessible sources of autologous adult stem cells in humans:

Bone marrow which requires harvesting by drilling into bone (typically the femur or iliac crest). This is done under a general anesthetic.

Blood, which requires extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and then returns the blood to the donor.

Adipose tissue (lipid cells), which requires extraction by liposuction.

Umbilical cord blood - these stem cells can be collected from the umbilical cord blood just after birth.

as sickle cell anaemia and aplastic anaemia. For most types of blood cancers, for example: leukaemia, lymphoma and various anaemia’s, the treatments use allogeneic stem cell transplants (someone else’s stem cells). The reason for this is that the person may have a genetic predisposition to the disease; their genes have a defect that predisposes them to that disease.

What can stem cells be used for today?

There are treatments where Hematopoietic Stem Cell Transplants (HSCT) - the transplantation of blood forming stem cells - is a standard treatment. For some diseases they are the only therapy, and in other diseases they are only employed when front-line therapies have failed or the disease is very aggressive.

However there are various types of cancers (some myelomas, plasma cell leukaemia, some anaemia’s and solid tumours) that are treated using autologous stem cells (using your own stem cells).

There are other blood disorders that can be treated with stem cells that aren’t cancers, such

https://leukaemiamyelomaresearchuk.org

Charitable Activities

Providing Information

Throughout the year we have shared facts about blood cancer, including the signs, symptoms and treatments. We have achieved this through our regular newsletter, social media channels, website, and our blood cancer booklet. This provides patients with clear and informative advice that would answer their questions, explain terminology, discuss treatments so they are better prepared and able to make informed choices.

We produce a monthly newsletter that shines a spotlight on our inspirational fundraisers and their stories; highlights our exciting plans for the future and provides information relating to blood cancer. It is available from our website free of charge.

Medical Research

Leukaemia & Myeloma Research UK allocate research grants to those who uphold our primary objectives. These

particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. Our current funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients. All grant applications are reviewed by the Charity’s

Research and Review

cancer in the family, to store their babies cord blood stem cells at the time of birth. These cells are stored for 25 years in case that child, or another member of the family, needs them in the future to treat a disease.

Committee, an independent panel of experts. The Charity is a member of the Association of Medical Research Charities, the AMRC.

Fundraising Activities

Over the last year, the Charity expanded its textile recycling project so it now includes local schools to the Merseyside and Greater Manchester areas. This is with the aim of raising awareness of both blood cancer and of the environmental continues to raise valuable funds for the charities work.

The cord blood stem cells can be used today instead of bone marrow stem cells to treat blood cancer and genetic disorders. In fact, recent studies show that over 80 diseases could be treated using cord blood stem cells.

In conjunction with this, our fundraisers have been busy running events from cake sales to sky dives. This has secured our services and help in the

Model Cell Biobank Service This service was established to support families who are on low income, have a history of

5

Chairman’s Report

But for our charity, this work goes on every day, 12 months a year. We are committed to educating people on the symptoms, so that the number of people diagnosed with the a year – are diagnosed and begin treatment sooner. We have produced an informative downloadable poster for people to print and share with family, friends, colleagues, and local community groups.

It’s been a busy year for Leukaemia & Myeloma Research UK (LMRUK) and we are celebrating the amazing support from staff, volunteers and fundraisers who enable our charity to continue our vital work.

and a “Donate Clothes by Post” option for the community, making it easy for people to donate their clothing to our charity and support our work.

We also want to be able to install clothing banks to make it easier to donate to the project.

Throughout the year we actively took part in national awareness days including Myeloma Awareness Month in March, Blood Cancer Awareness Month in September and World Cord Blood Day in November by sharing key facts and statistics, as well as stories from people directly impacted by blood cancer.

I would like to thank all our incredible fundraisers, volunteers, their families and friends who have supported them and our Charity. Without them, we couldn’t continue to offer the services that we do

working on the Donate Clothes launched at the beginning project is to raise extra funds by giving a second life to preloved clothing donated by the community. Local schools, community centres, nurseries and other establishments will be involved in the project, by offering a clothing collection service.

The biggest campaign is Blood Cancer Awareness Month and throughout September, charities across the country band together to shine a light on the three main types of cancer of the blood; Leukaemia, Myeloma and Lymphoma, which more than living with.

Serge Vinogradov

Chair, Leukaemia and Myeloma Research UK Ltd

The project will also offer a free “Book Collection” service

https://leukaemiamyelomaresearchuk.org

Operation Director’s Report

Alex Lewis, whose Grandad, is also undergoing treatment for blood cancer, as well as William Sudding and Lucas Heappey, both of whom wanted to support her and Alex in raising money for vital blood cancer research. They smashed their target and raised an

This year we have once again been supported by some incredible fundraisers. From skydives to kiltwalks and marathons, there has been a variety of fantastic fundraising events this year, including the Margot family, who climbed the Yorkshire Three Peaks in memory of Graham Margot – a beloved husband, dad and grandad who passed away in 2022. The Margot family were named the charity’s ‘Fundraiser of

They raised an incredible £2,500 for the charity.

Ashleigh Harris from South Wales, ran the Cardiff Half Marathon in October in memory of her close friend and former colleague, Rachel Stickler, who passed away from Acute Myeloid Leukaemia (AML). Inspired by Rachel’s running, Ashleigh joined her local running group – Islwyn Running Club – and set herself a goal of completing the for LMRUK.

Another amazing fundraiser was Chris Cattrall, who took part in the Dorney Lakes 5km race, raising over £1,000 for the charity.

charity’s funding comes from individual donations and fundraising events, highlighting the reliance on the generosity of supporters. We have so many incredible fundraisers, a few are highlighted below.

To mark a year since her husband’s passing, Wendy Forrest from Broughty Ferry in friends, took on the Mighty Stride Kiltwalk in Dundee to raise money for LMRUK. Wendy, who works as a Civil Servant, was joined by Suzy, Morag, Lynne, Jade and Sarah to complete the 20-mile walk to raise awareness of blood cancer in memory of Alan.

Tamara, a student at University of Leeds, ran the Leeds Half Marathon in May in support of her stepdad Richard Woods, who is currently receiving treatment for acute myeloid leukaemia (AML). She was supported by good friend,

She raised an incredible £1,000, original target.

I would like to say a huge ‘thank you’ to all our fundraisers for their hard work and to our dedicated staff team and partners who together have a huge success. All of our fundraisers are important - we simply would not be able to run these services without their help. Dr Joanna Tilley

12 members of the Kiwanis London South East Group took to the streets to complete an 8-mile fundraising walk for the charity. Winston Mason, walk in memory of his mother, Olive Campbell, who passed diagnosed with myeloma.

We are incredibly grateful to each and every one of fundraisers and to those who make donations to the charity in memory of loved ones. As a result of the funds raised this year, we awarded our highest to support two projects exploring and examining the causes of Acute Myeloid Leukaemia and Myeloma to blood cancer.

Operations Director, Leukaemia and Myeloma Research UK Ltd

https://leukaemiamyelomaresearchuk.org 8

MCB Service

Overview

The Model Cell Biobank (MCB)

service allows the storage of a child’s umbilical cord blood stem cells at the time of birth, in case they or another member of the family needs them in the future to help in the treatment of a disease. It may be possible to use the stem cells to treat blood cancers or in emerging therapies to treat diseases such as diabetes, cerebral palsy and Parkinson’s disease. Clinical trials are being performed all over the world looking at the potential use of stem cells to treat new diseases and hopefully further breakthroughs.

When a baby is born and the umbilical cord is cut, the placenta and umbilical cord are normally thrown away. The blood that remains in the cord and the placenta contains stem cells. The Charity offers a service to collect these stem cells without any risk to the mother and baby, and to store them in case that child or another member of the family needs them in the future. The cord blood stem cells are stored on behalf of the child for 25 years.

The mother is the legal guardian of the cells until the child reaches the age of majority, at which point, ownership transfers to the child. After 25 years, the cells can be privately stored, donated for research, offered to a public bank, or destroyed.Consent from the child will be sought at this point and we would strongly encourage the donation of any remaining cells to public banks.

We now offer a fully funded cord blood banking service to families who are universal credit with a history of cancer in the family.

Alongside this, we also offer a part funded service to low income families.

Smart Cells Technical is our chosen partner to procure; process and store cord stem cells under its Human Tissue Authority licence. Smart Cells has a strong reputation for the high standards it applies to the storage and processing of stem cells derived from

umbilical cord and peripheral blood, bone marrow, now extending to many types of tissues for human application or transplant.

Smart Cells not only works to the highest standards, it also has an ethical approach, which aligns with our charity, something we are proud of.

9

Advantages of Cord Blood Stem Cells

and infections and so the stem cells are less likely to transmit infection and react with the patient;

Today, cord blood banking is changing lives and there have already been more than one million stem cell transplants around the world since the 1980s.

Cord blood stem cells offer the life-saving option of a transplant and avoids the invasive, painful and expensive procedures of other stem cell collection, such as bone marrow;

The stem cells in a baby’s cord blood are fully developed adult stem cells, which are the building blocks of the blood immune system. These stem cells can be used instead of bone marrow stem cell to treat blood cancers and genetic disorders.

Cord blood stem cells can be stored for many years - the longevity of these cells has proved they extracted and stored.

Cord blood stem cells have many advantages including:

They are easily available, having already been harvested and stored;

A new born baby has been exposed to fewer viruses

Feedback from Clients

have found out about this potentially lifesaving service, and even if we don’t use the stored cord blood stem cells, it is reassuring to know that they will not go to waste.”

“Cord blood stem cell storage and transplants are very costly so many cannot afford to use this potentially lifesaving service. This would certainly have been the case for us.”

baby daughter’s cord blood stem cells. The collection was very quick –and within two hours of birth her cord blood stem cells had been collected from the hospital and taken back to Smart Cells Technical to be stored.”

“The whole process of retrieving the cord blood stem cells was very simple. When I was induced at the hospital we called the phlebotomist who arrived shortly after to take our

“Ever since my diagnosis I have felt an enormous sense of guilt about the chance of any of my children getting cancer – it is a mother’s worst nightmare. I am incredibly grateful to

https://leukaemiamyelomaresearchuk.org 10

Donate Clothes to Samm y

To generate additional revenue to support the mission and causes of LMRUK charity, the trustees approved the the newly expanded recycling project aptly called: Donate

The goal of the project is to raise extra funds by giving a second life to preloved clothing donated by the community via local schools, community centres, nurseries and other establishments.

Our recycling programme secures valuable funds for blood cancer and raising awareness of our work. It also promotes re-use and recycling and encourages sustainable practices.

The project also offers a free ‘Book Collection’ service and a ‘Donate Clothes by Post’ option for the community, making it easy for people to donate their clothing to our charity and support our work. The project has received strong support and a great response from the public, which has enabled us to provide additional services, including the installation of Clothes Banks for convenient collection of pre-loved clothing.

We plan to reach out to every week.

Combined with this we are hoping to purchase an additional 10 outdoor clothing banks which will be located in Liverpool and Manchester.

We expect the newly expanded recycling scheme to generate an extra £50,000 per year to allocate additional grants for research initiatives.

The project is managed entirely by the charity’s team without involving commercial companies, the proceeds go directly to the charity.

11

Research Priorities

Research Institute at Cardiff University, was awarded ground breaking research treatment for acute myeloid leukaemia (AML).

Leukaemia & Myeloma Research UK offer research grants to those who uphold our primary objectives: to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.

the disease of nutrients

She was awarded the Lister Wilder Research Grant of £22,500. If successful, their work will lead to the testing of new drugs in combination with current anti-myeloma medications in the laboratory and if deemed, in people.

The project was initiated in a master switch capable of new theraputic targets in AML.

The Trustees funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants.

Dr Concetta Bubici from Brunel University in London, received funding to continue her work investigating treatment for myeloma, by starving

the

Europen Cancer Stem Cell

Research Review Committee Members

Dr Rhys Morgan

Dr Paul Spencer Hole

Lecturer in Biomedical Sciences in Department of Biochemistry and Biomedicine, at the University of Sussex.

Senior Research Scientist. Has been engaged in academic research at Cardiff University and extends his experience in a clinical-stage biopharmaceutical company.

Professor Joseph R. Slupsky

Reader in Department of Molecular and Clinical Cancer Medicine, University of Liverpool. He is Principal Investigator of the Liverpool Blood Disease Biobank and Academic Lead University of Liverpool Technology Directorate Cell Sorting and Flow/Mass Cytometry Facility.

Dr Claire Seedhouse

Associate Professor within Division of Cancer and Stem Cells, University of Nottingham. She is Principle Investigator and research group leader in Blood Cancer at the University of Nottingham.

Dr Ceri Bygrave

A Consultant Haematologist and Myeloma Lead at the University Hospital of Wales and a member of the UK Myeloma Forum Executive Committee and the UK Myeloma Research Alliance.

Dr John Jones

Senior Clinical Lecturer – Brighton and Sussex Medical School, Honorary Consultant Haematologist – Kings College Hospital NHS Trust, London and Eastbourne District General Hospital.

Dr Salvatore Papa

An Associate Professor at Leeds University whose research speciality is in lymphoma and myeloma.

https://leukaemiamyelomaresearchuk.org 12

Fundraisin and Volunteers g

The Margot family were joined by close friends as they took on the Yorkshire Three Peaks challenge

The Margot family were joined by close friends as they took on the Yorkshire Three Peaks

research into stem cell therapies as a more effective treatment, so we can help to protect the next generation.

The group climbed all three peaks in 12 hours Margot – a wonderful husband, dad and grandfather - who passed away in August 2022.

Graham was diagnosed with Chronic Myelomonocytic Leukaemia (CMML), which infection caused by a previous ailment – in this instance, diverticulitis. Due to the infection, his bowel perforated and he developed sepsis, a life-threatening reaction, and sadly passed away surrounded by his family.

Graham’s daughter, Emily said: “After setting our fundraising target believe that we’ve now raised almost £15,000

The group did incredibly well and we are all so proud that they’ve completed this mountain of a challenge to help support vital blood cancer research.

“My dad would have hated all the fuss that we’ve done in his memory, but we know he’s looking down on us all and feeling very proud.”

Dr Joanna Tilley, Operations Director at LMRUK added: “There are over 100 types of blood cancer, many of which are extremely rare. Our charity is committed to funding vital

So many people mistake the early signs and symptoms with something else, so we’re encouraging people to educate themselves and others on what to look out for, and if something isn’t right, go to your doctor to get checked out.

“None of our work would be possible without the support and tenacity of our fantastic fundraisers, including the Margot family, who have done such an incredible job of thank them enough.”

To read the Margot’s story, visit

Furthermore, LMRUK were delighted to announce that our Fundraiser of the Year is....

A huge congratulations to everyone involved and a massive thank you for their fantastic fundraising efforts.

The group who completed the challenge was Anna, Graham’s wife, and Emily’s brother, Oli, brother-in-law, Sam, and husband, Alex, as well as close friends; Charles, Jonny, Jamie, Julio, Emily, Robbo and Sharon.

This is just one of the many fantastic fundraisers that have kindly supported LMRUK over the past year - we simply could not run these services

Thanks to Funders

Lloyds Bank Staff

• N Smith Charitable Settlement Robert Luff Foundation Mackintosh Foundation Orange Tree Trust Hilary Awdry Charitable Trust The Medicash Foundation Hospital Saturday Fund Michael Watson Charitable Trust

• Marsland Mcadoo Charitable Settlement

• Hemby Charitable Trust

• Hudson Charitable trust

• Barratt Developments PLC CharitableFoundation

• LCVS Eli Lily and Co Speke Ops

• Golders green Foundation Belvedere Trust Dalgleish Trust Sunset Charitable Trust

• John Mason Charitable trust

• Prowting Charitable Foundation

• Worcester Bosch

• L and R Gilley Charitable Trust

• The James Dyson Foundation

Staff and Trustees

Trustees

• Sergejs Vinogradov (Chair)

• Tatjana Vinogradova

• Victoria Kieran

• Julija Sidorika

Staff Team

Dr Joanna Tilley - Interim Operations Director

• Richard Thompson - Call Centre

Thanks to Individuals and supporters

Best Freelance Design Ltd

• Smart Cells International

• West Lancs & Merseyside Myeloma Support Group

• Fundraising Support Ltd

• KOR Communications

• Phlebotomy UK Ltd Research Review Committee

• Lister Wilder

• Kate Williams - PT Fundraiser

• Karina Zaiceva - Project Manager

https://leukaemiamyelomaresearchuk.org

Income and Expenditure Account for the year ended 31st March 20

leukaemiamyelomaresearchuk.org Registered charity number 1161622 (England & Wales), SC046106 (Scotland), Company Limited by guarantee Registered number 09481278

Leukaemia & Myeloma Research UK Ltd Report and accounts for the year ended 31 March 2024 Contents Page Charity information Trustees. Annual Report Statement of directors, responslbllltles Independent Examiner's Report Funds Statements... Statement ol Financial Activities 10 Slalemenl of Fin8nci81 Activities- Prior Year stslemenl Movements in funds 13 Incorne and Expenditure account 14 Balance sheet 15 Note8 to the accounts 17

Leukaemia & Myeloma Research UK Ltd Company Registration Number- 09481278 Trustees, Annual Report for the year ended 31 March 2024 The Trustees present their Report and Accounts for the year ended 31 March 2024. which also ¢omprises the Directors, Report required by the Companies 2006. Reference and administrative details The charity name. The legal narne of the charity 18.'- Leukaemia & Myeloma Research UK Ltd. The charity 18 al80 known by its operating name, LMR UK Ltd The charitys areas operation and UK charitable registration. The chaiity is iegistered in England & Wales with the Ch3rity Cornmis5ion in England & Wale5 ICCEWI wth charity number 1161622. The ¢harity is also registered in Scotland. with charity number SC046106 as it has operations in S¢otland. The charity does not operate In any overseas jurisdictions. Lggal stru¢tur• of tlw char The charity is constituted as a company limited by guarantee. ￿gIStered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association estsblishing th8 company under company legislation. The governing document is dated 10 March 2015 There are no reslriclions in the governing documents on the operation of the Charity or on ils investment powers other than those imposed by Charity Law. By operation of law all, trustees a￿ ￿1￿CtorS under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under t>oth company and charity legislation. The truste88 ar8 811 individual5. The prlnclpal operatlng addre$$, telephone number, emall and web addresses of the charlty are:. Unit 127, North Mersey Business Centre Woodward Road. Liverpool Merseyside, L33 7UY Telephone [phone] Email Address [e-mail] Web address https."Ilwww.leukaemiarnyelomaresearc The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

Leukaemia & Myeloma Research UK Ltd Company Registration Number- 09481278 Trustees, Annual Report for the year ended 31 March 2024 The Trustses in office on the date the report was approved were'.- Sergejs Vinogradovs Taljana Vinogradova Julija Sidorika Victoria Kieran The followlng persons seNed as Trustees durlng the year ended 31 March 2024 :. The trustees who served as a trustee in the reporting period were as Shown above. and there were no changes during the year. or in the period be￿een the year end and the approval of the accounts. All the trustees are also members of the charity. Objects and actlvltles of the ¢harlty The purposes of the charity as set out in its governing document. The objectives of the charity are set out In the Memorandum of Association of 14 July 2015. They are.. 1. to protect and promote the health of the publi¢ in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. 2. development of research into practical applications for the prevention. Treatment and cure leukaemia and myeloma and raise public understanding of such matters. The main activities undertaken in relation to those purposes during the year. Research grants are provided in order to promote the health of the public by research into the nature, cause, disnoses, preventon, treatment and cure of leukaemia and myeloma. The main activities undertaken during the year to further the charity s purpose ftir the public benefit. Two ￿SearCh grants were provided this year lolalling £57,500.00 Public awareness was a big focus this year with the charity undertaking the project of collecting clothes and selling these to raise funds. The trustees have had regard to the Charity Commission's guidance on public benefit in fflanaging the

Leukaemia & Myeloma Research UK Ltd Company Registration Number- 09481278 Trustees, Annual Report for the year ended 31 March 2024 The main achievements and performance of the charity during the year. As advised, the charity have been able to provide two large grants for research purposes. There was a large increase in awareness via the donation of clothes. More ftjnds were in turn raised to Support the charity. The difference the charity s performance during the year has made to the beneficiaries of the charity and wider society. The ¢harily was able to raise alol more funds this year which in tum raised awareness of the disease. This has benefited the wider society with more people being aware of the effects and the importance of research to support those living with the disease. Structure, governance and management of the charity The methods used to recruit and appoint new charity trustees. Proposals for new Trustees are made by the Chair after making appropriate enquiries. Appointments are then made by election by the existing board of Trustees. The trustees'bankers and advisors Accountants KBH Accountants Ltd- 255 Poulton Road, Wa11asey, CH44 4BT Financial review The charitys financial position at the end of the year ended 31 March 2024 The financial position of the charity at 31 March 2024 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows"_ 2024 2023 Net Income 37,883 35,474 Unreslri¢led Revenue Funds available for the general putpose5 of the charity 346,737 311.735 Restri¢ted Revenue Funds 43,467 40.586 Total Funds 390,204 352.321 Financial review of the position at the reporting date, 31 March 2024 .

Leukaemia & Myeloma Research UK Ltd Company Registration Number- 09481278 Trustees, Annual Report for the year ended 31 March 2024 Overall surplus stsnds at £390,204 and will be distributed in the following way.. £150,000 for the Reserves.. £25.000 for Research Grants, and £215,204 for charity development, including MCB, e- shop, and the Donate Clothes 4 Sammy project. The trustees consider the financial performance by the charity during the year lo have been satisfactory. Policies on reserves. The trustees collectively aim to maintain free reserves in unrestricted funds wthin a range equivalent to ￿￿e1ve months of unrestricted charitable expenditure. This targeted level is deemed essential by the trustees lo ensure an adequate financial cushion for covering support and governance costs. The Reserves Policy wll undergo an annual review, aligning with the scrutiny of the charity's annual accounts. In light of the events of the past year, marked by a significant surge in inflation, escalating living costs, and an increased risk of economic downturn, the Iruslees have determined that a prudent Reserves amount must be sel at £150,000. This decision is reflective of the charity's commitment to financial resilience and ils responsiveness lo the evolving economic landscape. Availability and adequacy of assets of each of the funds The board of trustees Is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund. Detalls of The Independent Examlner Olivia Higgins FCCA Member of Chartered Certified Acncuntants 255 Poulton Road Wallasey Wirral CH44 4BT

Leukaemia & Myeloma Research UK Ltd Company Registration Number- 09481278 Trustees, Annual Report for the year ended 31 March 2024 Statement of the Directors. and Trustees. Responsibilities The charills trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006. the Charities Act 2011 and the Charities (Accounts and Reportsl Regulations 2008. NobNithstanding the explicit requirement in the extant statutory regulalions,Ihe Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined lo interpret this responsibility as requiring them lo follow current best practi￿ and prepare the accounts according to the FRS 102 SORP Islatemenl of Recommended practi￿ for Accounting and Reporting by Chariliesl 2019, applicable lo all accounting periods beginning on or after 1st January 20191, (The SORPI, In particular, the Companies Act 2006 and charity law require the Board of Trustees lo prepare financial statements for each financial year which give a true and fair view of the slate of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial stslemenls the Board is required lo lo prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable lawl. select suitable accounting policies and apply them ¢onsistenUy', make judgements and eslimales that are reasonable and prudent., prepare the financial statements on the going concem basis unless il is inappropriate lo presume that the charity will continue in business., stsle whether applicable accounting standards and slalemenls of recommended practice have been followed, subject lo any material departLJres disclosed and explained in the financial statements.. The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the slate of affairs of the charity and of the surplus or deficit of the charity for the year. The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any lime the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for tsking reasonable steps for the prevention and detection of fraud and other irregularities. The Ttustees are also responsible for the contents of the Ttustees, report, and the statutory responsibility of the Independent Examiner in relation to the Trustees, report is limited to examining the report and ensuring that , on the fa￿ of the report, the￿ are no material inconsistencies with the figures disclosed in the financial statements.

Loukaomla & Mygloma Research UK Ltd Corywny Reoistralion Number- 09481218 Trustees. Annual Report for the year ended 31 March 2024 Mothod of preparatlon of accounts . Small company provlslon8 The financial statements are sel out on p8g8s 10 to 36. The financial statements have be8n prepared implgmenling th9 FRS 102 SORP IStalem8nl of R8CDmmend8d Practice for Ac¢ounllng and Roporting by Charities) 2019, applicable to all a¢counUng perfods beginning on or after 1st January 20191. SORPI, and in aCcO￿l8n¢0 wlth thA Fin2nr.ial Rp.nnrtlnn gFandArd 1 n? (AffAP.IivA 1st.IAniiAni ?n1fi) Th&se finandal statements have b¢en prgpared in accordance ￿th the provlslons In Part 15 of thè Companios Act 2006. appIl￿ble lo companles sublecl lo the small Companies regime. Thi$ r8FX)rt wa8 8pprov8d by the iM)8rd of trus18e8 on 2024. TATJANA VINOGRADOVA Director and Trust88

Leukaemia & Myeloma Research UK Ltd R•port of thè In(lepèndènt Examln•r to thè Trust•ès of th& charltsble company on the aeeounts for the year ended 31 March 2024 I report lo the Trustees on my examination of the financial statements of the charitable company on pages 10 to 36 for the year ended 31 Marth 2024 which have been prepared In accordan￿ with the Charities Act 2011 (the Aeti and with th? Financial R8porting Standard 102. leffective 1st January 20161 as modified by FRS 102 SORP Slalement of Recomrnended Practice for Accounting and Reporting by Charities12019, applicable lo all accounting periods beginning on or after 1$1 January 20191. (The SORPI, published by the Charity Commission in England & Wales ICCEWI and under the historic21 cost convention and the accounting polici88 Set out on page 17. Respoctive responsibilities of the Trustees and the Independent Examiner and the basis of the report As des¢ribed on page 5, you. the Charitable ¢ompanys Twslees. who a￿ also the Dire¢lors of the Company for the purposes of Company law. are r&8pon8ibl& for the preparation of the financial 818lements in accordance with the Companies Act 2006. the Charities Act 2D11 and all other applicab￿ law and wlh United Kingdom Generalty Acopted A¢¢ounbng Practio, applicable to smallerentitves. and for being satisfied that the financial statements give a true and fair view. The Trustees consider that the audit requirement of Section 144111 of the Charitie8 Act 2011 (the Acll does not spply, and that there is no requirement in the rn8morandum and artic￿ of the charity for the conducting of an audit, and that the account5 do not require an audit in accordance with Part 16 of the CotnpanEs Act 2006 and that no member or members have reque$ted an audit pursuant to Se¢tion 476 of the Companies A¢1 2006. As a con88quence, the Tru8188s have 818cl8d that the financial statements be subject to independ8nt examination. Having satisfied myself that the financial statements are not required to be audited under any legal provision. or otherwse, and are eligible for independent examination, il is rny responsibility to.'- al examine tt)e financial statements of the ¢harily under Section 145 of the A¢t', bl follow the applit2ble pro¢edure$ In the Dire¢tion$ given by Y)e Charity Gommission under $e¢tion 1451Sllbl of the Act. Ba515 of Independent Exarninerfs Ststement and scop8 ofwork und8rtak8n Since the Charrtab￿ companls gross income exceeded £250,000, th? charitable company's examiner musl a member of a body listed in section 145 of the Act. I confirm that l atn qualrfied to undertake the examination because l am an authorised member of Charte￿d Certified A¢o¢untsnls whi¢h is one of the listed bodies. I report in re5P8Ct of my 8xarninstion of the charity's financial statements Carri￿ out under $145 of the Act. In carrying out My exarnination, I have followed all the applicable Directions given by the Charity Cotnmi55ion under 8eclion 14515llbl of the Act setting out thè duties of an Independent examiner in relation to the conducting of an indep8ndent examination. An independent examination includes a review of th8 accounting records kept by the CharItsb￿ company and of the accounting 5y51ems employed by the charitsble cornpany and a cornparison of the financial slalements p￿sented with those re¢ords. It also In¢lude$ unsideration of any unusual Items or disdosures in the financial slatemenls, and 8&&king explanations from you, as Trustees, concerning such matter8. The purpose of the examination is lo establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evideno relevant lo the amounts and disdosures made. the finanual statements ¢omply with the SORP. The procedures undertaken do not provide all the evidence thalwou￿ be requir8d in an audit, and information Supplied by the Trustees in the course of the examination is not subjected lo audit tests or enquirie5 and does not cover all the matters that an auditorwould consider In arriving at an opinion. The planning and ¢ondu¢t of an audit goes beyond the limited a88uran(£ that an inderendent examin8tion ean provide Cons8quently, I do not &xpress an audit opinion on the view given by the financial statements, and in particular, I express no opinion a5 to whether the financial statements give a true and fair of the affair5 of the charity. and my report is limited lo the matters sel out in the $tatemenl below.

Leukaemia & Myeloma Research UK Ltd I Plann￿ and perf0rn18d my gxamlnatkjn $0 a5 to a￿Sfy mysoff that the oLryecliv85 oflh8 indeFend8nl 8xaminallon ar8 achvaved and ￿fOr& finall$1￿ the roP)rt l oblalned vthEt0n gSSUvan(￿ ftotn the T[ust￿$ of all rnat8r￿ malier8. Indèpondènt ExamIne￿5 Statement, Report and Oplnlon Attgnllon b drawn t(k the accOu￿tIng pollcy Blatiw that. nolwilh$tandI￿ Iho &xpli(4t roquliomont In th8 èxtant 6taluiory rogula￿On$, tho Charlties IAccounts and Rwrtsl ReoulatiM$ 2008. to prepar& the IKian¢ial statom>nts In a￿ard8n¢￿ wth lh8 SORP 2005, in y￿Wof Ihs fact thattho SORP 2005 has bg8n ithdravm. and ￿ ord8r to actord ilh curient best practic8, thg Trusteès hava d&larmlned to preparo th$ Ilnanclal stateinents in accordanc8 with tha FR$ 1tr2 SORP Islatomont of Recomm￿￿ed Piactic8 forAccouThting arNI Reporting by cha￿11t812019. applica1￿8 lo all a¢tounllng p￿0d$ beginning on or aftèt 1$t January20191, (rh8 SORPI. I concur with this appro**, and any r8f8r8nc8s In my Y8POrt lo the regulalh)ns 8houhJ bp read 5ublgct to this cotntn8nt. &Jbjodb ihe Ilrnitall￿8 upon the 6cope ol my %wtk as dètsilèd abov8, I have my exa￿Da￿On. and Can confimi thaL._ Th& of thls charStab18 company 9T8 ￿t r8quwod to be audited undor Part 16 of th• CompsniesAct 2(￿., Th8 utoss inccfn8 oftha d)arltaNe company In the w ended 31 Marth 2024 arvear810 exc￿1 ths sum 8peoffi&d In Socllon 145(31 olthe Act, nam8ty £25WOO, and that l am qualified lo oct es Independent ExHminer in accordar￿& vAth Ihal sacllon by virtue ol my bèlno a qua1rf18d m8rnberof charter￿ cartifi￿ A￿UnI8n￿.' Thls Is a r6P)rt In r¢$po¢t of an oxamlnation carried oui und8r t45 of the Act and In a¢¢(¥dartD ￿1h t￿re(￿on5 gni8n ty CharityQpmmissk)n under 14515llbl of the AGtwhich m8y b8 8pplicabl8', and that no material fflattgr8 havg com8 lo my altentI￿ in conno¢tion vAth tho 0X￿￿at1￿9tr¥Ing mo to belev8 Ihal in any material r8sp8Ct.'- accfjuntinu r8cords wero nol kèpt In w$peGt ol tlp ¢harity as r￿UIred by Soction 386 of lh8 Compani8s Aci 2(K)6 and Se¢ts"ckn 130 of Th& Charides Aci 2011. the financlal 8tstements do mt wid ￿ thosè racords.. or tho flnan¢lo1 statgmgnls do mt complywth the applicable r8qulr£manls c0n¢èMl￿ thg form and wntont of acmunts $81 out in 88clion 396 01 thg Comwanies M 2008 oihgr than any r8quirernent that the account8 gDIÈ ,tll￿ a￿1 fair. ¥￿, 18 nol g mattèr t￿61dered 98 Part ol an Ind&p￿mI￿nt examinatim,. h8Ya not bean wepared in ac(x)rdan¢• with tho mèthLxls princip188 88t out in th& FRS 102 SORP IStat8m8nt of R8coJnm8nd8d Pr8ctic8 for Arxx>un¢ing and Repor￿￿ by Charitièsl 2019. Mppllcoble to 811 acAxursting periods baginning on or aftor 1st January 20191, ITh8 SORW. I havg no concorns 8nd have u)m8 &yoss no othor mal¢srs In ¢onna¢tion ￿th tho gxaminatfv)n lo ththlch attention Sho￿d be drawn in tINs report ￿ order to 8natrAe o woper under8tandino olthe linandal stat8rnènts to be reaGhgd. OINia Higgins FCCA- Ind0p•￿ant Examlnèr charlor￿ C8rtifi8d ACocunt￿ts 255 Poutton Road WallasBy Wirr GH44 4BT Thls rem was 81gn8d on 2W24

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2024 Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2024, as required by the Companies Act 2006) SORP R81 Curr8th year Unrestricted Fut)d8 Current yoar Restricted Fund8 Current year Total Funds Prloryoar Total Funds 2024 2024 2024 2023 Income & Endowments from= Donations & Legacies Charitable activities Investments Other A1 191,132 63,177 4,317 50,000 51,705 242,837 63,177 4,317 60,000 173,975 20,553 665 50,063 A4 A5 Total income 308,626 51,705 360,331 245,256 Expenditure on: Raising funds Charitable activities 81 B2 14,389 259,235 14,389 308,059 19,100 190,682 48,824 Totsl expenditure 273,824 48.824 322,448 209,782 N8t income forth8 y8ar 35,002 2,881 37,883 35,474 Net movement in funds 35,002 2,881 37,883 35,474 Total fund5 brought forward 311,735 40,586 362,321 316,847 Totsl funds ¢arrled foTrward 346,737 43,467 390,204 352,321 The'SORP Ref indicated above is the clas51fication of income Set out In the formal SORP docurnents. A5 required by Paragraph 4.60 of the SORP. the brought forward and carried forward funds 8bove have been agreed to the Balance Sheet. A separate Statement of Total ReC￿nISed Gains and Losses 18 not required as this statement includes all recognised gains and losses. All the prior year transactions were unrestricted itern5, and no further anslysis is required All activities derive from continuing operations The notes attached on page5 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2024 Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds. as required by paragraph 4.2 of the SORP Prlor Y•8r Prlor Y8ar Prlor Y￿r Total Funth SORP Ref Unrestrlctsd Funds Restrlctod Fund5 2023 2023 2023 Donations & Legacies Charitable activities Investments other A1 173,975 20,553 665 50,063 173,975 20,5S3 665 SO,063 A5 Totsl In¢ome 245,256 245,256 Expenditure on= Raising funds Charitable activities 81 B2 19,100 190,682 19,100 190,682 Totsl expenditure 209,782 209,782 Net income forthe year 35,474 35,474 Net movement in funds 35,474 35,474 Total fund5 brought forward 285,330 31,517 316,847 Totsl fund$ ¢arrled forward 320,804 31.517 352,321 All activities derive from continuing operations A separate Statement of Total Recognised Gains and Losses is not required as thi5 Stat8rnent indudes all recognised gains and losses., The notes attached on pages 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2024 Leukaemia & Myeloma Research UK Ltd - Resources applled In the year ended 31 March 2024 toward5 fixed a55ets for Charity use:. 2024 2023 Funds generated in the year 88 detailed in the SOFA Resour￿5 applied on functional fixed asset5 124,5701 11,5991 Net resources avallable to fund charltable actlvltles 124,5701 11,5991 The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals. The notes attached on pages 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2024 Movements in revenue and capital funds forthe year ended 31 March 2024 Revenue accumulated funds Unrestricted Fund8 2024 Restricted Funds 2024 Totsl Funds 2024 Lastyear Totsi Fundts 2023 Accumulated funds brought fonward 311,735 40.586 352.321 316,847 Recognised gains and losses before trsn5fer5 35,002 2,881 37,883 35,474 346,737 43,467 390,204 352,321 IFromlTho restricted revenue funds Closing revenue funds 346,737 43,467 390,204 352,321 Summary of funds Unrestrfcted and Designated funds 2024 Restrleted Funds Totsl Funds Last Year Total Funds 2024 2024 2023 Revenue accAJmulated funds 346,737 43.467 390,204 352,321 Total funds 346,737 43,467 390,204 352,321 The notes attached on pages 17 to 36 form an integral part of these accounts. 12

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2024 Leukaemia & Myeloma Research UK Ltd Income and Expenditure Account for the year ended 31 March 2024 as required by the Companies Act 2006 2024 2023 Income Income from operations 306,014 194,528 Investment income Interest receivable Other operating inwme 4.317 50.000 50,063 Gros5 income in the year before exceptional item5 360,331 245,2S6 Gross Income In the year Includlng ex¢eptlrJnal Items 360,331 245,256 Expendfft￿re Charrtable expenditure, excluding dep￿ciatIon and amortisation Depreciation and amortisation Fundraising costs 300,892 7.167 14.389 189,657 1,025 19,100 Total expenditure in the year 322,448 209,782 Net Income tsefo￿ tsx In the flnan¢lal yeor 37,883 35,474 Retained surplus for the financial year 37,883 35,474 All activities derive from continuing operations In accordance with the provisions of the Companies Act 2006. the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charrty's activities.

Leukaemia & Myeloma Research UK Ltd - Balance Sheet as at 31 March 2024 SORP Nots Rof 2024 2023 Flxod a88ats Tangiblè 8ss8ts 19,227 1,824 Total flxe(l ass•18 19.227 1,824 Current assets stocks DebtDr5 Cash Bt bank and In ha￿1 B1 B2 27.319 12,326 335,511 17,490 5,060 333,510 Total currant bg¥ets 375,156 356,060 Cr•dltors: amounts falllng duo wlthln ¢ne year 9 C1 4,179 5,563 Net curront assets 370.977 350,497 The totd nol assets of thg charity 390,204 352,321 The total not assets of th• charlty ar8 fvndgd by the funds of the Charlty. aB follow8:. Rostrlctod funds R&strlctod R￿onUe Funds 11 D2 43,487 40,586 43,467 40,586 UnreBtrfcted Funds Unreslrlcted Revenue FuThJ5 11 D3 346.737 311,735 346.737 311.735 Total ¢harityfunds 390,204 352,321 Thè 'SORP Ref indicated above Is the elasslflcBllon of Balance Sheet ilam8 as sel out In the forrnal SORP docum&nts. As requirod by paragraph 4.60 ofthe SORP, the brought forward and carrfed forward funds abov havo been agr9ed to the SOFA. The dirgCtor8 arg sa￿st18d that the company is entitled to exemptSon from th8 r8quir8mènt to obtsin an audll under sectKin 477 01 the Companles Act 2005. Thg tllgrnbgrs have r￿1 required the company to obtain an audlt In ￿cord8n¢$ wllh secllon 476 of the Act. The directors ackrbjwledge th¢lr ￿sPOnSIbl1rtlQs for complylng wmh the requirements of the Companlas Act 2006 with raspact to accounting records and Ihe weparauon ol accounls. The charity Is subject to l￿1&pand8nt Ex8minatlon under charity legislation, and the report of Iha Indepond¢nl Examiner is on pagp g. Th8 ffinanclal statements have baen prgpared In ac¢ord8n¢& wlh the provisions in Part 15 of the Companles Act 2006. 8pplieabl8 to ct)mp8ni8s subject lo the small companles regime. TATJANA VINOGRADOVA Trustee Approvod by tha board of twstèe8 on //Dtetm lÉf2024 Th• notos •tta¢hed on page6 17 to 36 forn) an Integral part of thes¥ a￿Ounts. 14

Leukaemia & Myeloma Research UK Ltd Notes to the Accounts for the year ended 31 March 2024 1 Accounting policies Pollcles relatlng to the productlon of tho accounts. Basls of preparatlon and accountlng conventlon The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordsnce with th8 Finantial Reporting Standard 102. leff&clive 1st January 20161 and 'FRS 102 SORP Istatemenl of R&commended Pra¢ti forAccounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 20191, IThe SORPI, published by the Charity Commission In England & Wales ICCEWI , and in accordante with all applicable law in the charity's jurisdiction of re9istralion. except that the charity has p￿Pared the financial statements in attordance with the FRS 102 SORP (Statement of Recommended Practite forAtctrunting and Reporting by Charities) 2019, applicable lo all accounting periods beginning on or after 1st January 20191. (The SORPI, in preference lo the previous SORP. the SORP 2005. which has been withdrawn, notwithstanding the fa¢1 that the extsnl slalutory ￿gUlatiOns. the Charities IAccounts and Reports) R8gulstions 2008 refer ewlicrtty to the SORP 2005. This h85 b8en done lo accord with ¢Jrrent best po¢tice. Going Concern The charitable a¢livitie$ are entirely dependent on ¢ontinuing gffjnl aid and voluntary donations as well as trading ￿￿enueS. As a consequence, the going concern basis is dependent on the future flow of these uncertain funding strearns. A¢¢ordingly. the Trustees have obtained f0￿caSts and. after ￿￿le￿n9 the financial forecasts for future periods, tt)e Trustees are satisfied that, at the lime of approving the fi'nancial ststements. il is appropriate lo adopt the going concern basis in P￿paring the financial statements Other than these mallers. the Trustees are not aware of any material uncertainites about the charity's ability lo continue as a going concern. Policies relating to categories of income and income ￿cognItIon. Nature of incom8 Gross income represents the value, net of value added tsx and discounts, of goods provided to customers and work carried out In respect of 8ervices provided lo customers. Categories of Income Income is categorised as incotne from exchange transactions l¢ontra¢t in¢tsmel and income from non£xchange transactions Igiftsl. investment incom8 and oth&r Income. Income frorn exchange transactions is received by the charity for goods or service5 supplied under contract or where entitkment is subject to fulfilling performance ￿lated conditions. The In¢ome Y)e ¢harily re￿iVeS is approximately equal in value to the goods or services supplied by the charity lo the purchaser. Income frorn a non*xchange transaction is where the charity receives value frotn the donorwilhout providing equal V21uè in exchange, and includès donations of money. goods and services freely given without giving Èqual valuè in exchange. Income recognition In¢ome, whether from exchange or non ex¢hange transactions. is recognised In the statement of finan¢ial a¢tivilies ISOFAI on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entiyemenl. the Income Is probable and tan be measured reliably. Dividends are atcrued when the Shareholder's r￿ht to receive payment is established. Income subject to terms and tonditsons which musl be met before the charity is entiyed lo the reSoUr￿S is not recognised until the conditions have been met. l income is accounted for gross, before deducting any related fees or cost5. 15

Leukaemia & Myeloma Research UK Ltd Notes to the Accounts for the year ended 31 March 2024 Income from lÈgacles Income from I￿3cleS is recognised when the charity has sufficient eviden￿ that a grft has been left to them. that where required. probate has been granted, the executor is satisfied Ihal the property in question wll not be required to satisfy claim8 in the estate, that il is probable that the amount will be received by thè charity, and the amount to be reeeived can be estimated wlh surr1￿ent accuracy. and that any conditions attached lo the kgacy are either within the control of the charity or have been met. Where a payment is received from an est818 or is notified as receivable by the executors after the reporting date and b8fDre the a¢¢ounts ao authonsed for issue but rt is clear that the payment had been agreed by the exe¢utots prior to the end of the reporting period, then the amount concerned is treated as 8n adjusting event and accrued as income in the accounting period if receipt is probable. Where the tharity has estsbli5hed entitlernenl to a legacy but there 15 un￿rtaInty a5 to the amount of the payment, details of the legacy ared18c108ed as a contingent asset until the criteria for income recognition are mel. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as incotne until the death of the life tenant. If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made lo reduce the arnount of the legacy debtor and legacy income rather than ¢harging the adjustment as expenditure in the Statement of Financial Activities Donated goods, facilities and Services Donated flxed assets are re¢ognised at Y)e Current tsir value. Al such donations are recognised as donation income. and debited to fixed a88el8. Donatgd goods that arg not fixed assgt5 are accounted for at a fair value, unless It is irnpraclical to reliably measure the value of the donated items. In the absen¢e of any dI￿¢t ev1deTh￿ of fair value of donated goods. then a value Is derived from the ¢ost of the Item to the donor or. in the case of goods that are exp&cl￿ to be sold, the eslimal8d resale value after deducting any anticipated costs of sale$. If It Is impra¢ti¢able to measure the fair value of goods donated for resale. or the costs of valuation ouiweigh the benefrts. the donated goods are recognised as income when sold. with an equivalent amount ￿Ing recognised as an expense. The costs of goods donated for distribution to beneficiaries is deemed lo be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the Carrying amount 1$ adjusted al the time of sa￿, to the value at the point of distribution and the adjustment is shoNvn as 8 cost of donations made. The tarying amount of any stock held for distribution is assessed for impaimient al the reporting date. All don2ted goods are recognised as donation income, and debited to trading stock.when trading stock is subsequently sold, or appropriated to meet an èxpense, then the carrying value of the stock is re¢ffjnised as an expense. In accordan￿ with the SORP. goods donated for distribution to beneficiaries, or for consumption by the charity ar8 included in 18gaGies and donations, Goods donated for resale are induded in Income from otherlrading actwities, The cost of any 51ock of goods donated for distribution to beneficiarie5 is deemed to be the fail value of those gifts al the time of their receipt. If the good8 h&ld are to be distributed freely or for a nominal consideration. then the carrying amount is subsequeDlly adjusted to reflect the lower of deerned cost adjusted for any105s of service potential and replacetnent Cost. Rep18cement cost Is the economic cost incurred If the charity was to replace the service potential of the donated goods at its own expense in the most economic manner. Donated services and facilit185 (including seconded staff and use of property) are included in the accounts on the basi5 of the value of the gift lo the ¢harity- I donated sewi¢es and fa¢ililies are re¢ognised as donation Income when re¢eived.Iprovided the value of the grft Can be measured reliabtyl and recognised as an expense with eqUiVa￿￿t value. 16

Leukaemia & Myeloma Research UK Ltd Notes to the Accounts for the year ended 31 March 2024 Policios r•latirtg to oxponditure on goods and s8rwicos provid•d to thè charity. Recognition of liabilities and 8xp8nditure A liability, and the ￿lated expenditure, is ￿cOgnised when a legal or ¢onslrudrie obligation exists as a result of a past event, and when il is more likely than not that 8 transfer of economic benefi'ts will be required in settlement, and when th8 amount of the obligatlcin Can be measured or reliably estimated.. Liabilitie5 arising from fuluie funding cornmilments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required lo settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increase5 In liabilities, and is dècreased by the ulilisation of any provision within the period. and reversed if any provision 18 no longer required. These movements are charged or ￿e￿rted to the respective fund5 and activities lo which the provision relates. Allocating costs to activities Direct costs that a￿ spe¢ifi¢ally ￿lated to an activity are allocated to that a¢twity. Shared direct costs and support ¢osts a apportioned beh¥een activities. The basis for apportionment, which is consist8nlly applied, and proportionate to the circumstances, is:_ Staffing- on the basis of lime S￿nt in connection with any particular activity. Staffing- on a per capita basi5. based OD the number of of people employed within any partiular actwity. Premises related c05ts- on the proportion of floor area occupied by a particular activity. Non speclflc support costs- on the basis of the usage of re80urces. In terms of time taken. eapacity used, ￿queSt made or other measures Pollcles relatlng to assgts, Ilabllltlos andpmvlslons and othgr matters. Tangible fixedassets Tangible fixed assets are meaSu￿d al their original ¢ost value. or subsequent revaluation, or rf donated, as described above. Cost valu& includ&s all costs expended in bringing the asset into its intended working condition. Dèpreciation has been provided at the following rates In order lo write off the a88et8 to their anticipated residual value over their estimated useful lives. Plant and machinery Motor vehicles 25 OA 81raight line 25 % straight line A regU￿r annual review of the likelihood of asset impairment 18 undertaken. 17

Leukaemia & Myeloma Research UK Ltd Notes to the Accounts for the year ended 31 March 2024 Accounting for capital grants and fixed asset funds. Grfts tsf tsngible fixed assets or gonls of a capital nature, given for the purposes of a￿Ul￿ng spp¢rfi¢ assets lo bp fulty utilised in the further8ne8 of the objects of the charity, are cr8dit8d to fixed asset funds after the donated asset has been received or sutns have been propedy exFEnded on the restricted purpose. Where the terms of the gift require the charity to hokj the asset on an ongoing basis for a specffjc purpose. then the fixed asset fund so created Is calegorised as a r&81ricled fixed asset fund, and the relevant re81riclion8 are noted in th& fL%ed asset note 6. Where the terms of the gift are met onc* the a8sel is acquired. so allowing the charity to use the asset on an unrestricted basis. including the right lo reTrive the proceeds of any future sale of the asset on an unrestricted basis. then the Iixed asset fund so created 18 calegorised as a designated fixed asset fund. When assets are acquired for the furtherance of the charilvs objects, ulilising the charty's own unrestricted funds, a transfer is made from unrestricted funds to a designated fixed asset fund. Whether acquir&d with unreslricled or restricted funds, the asset acquired is initially shown in the balance sh88t al the full cost of acqui$ition or subsequent ￿valUatIon. As the related assets are depreciated, in )￿ordants with the depreciation poli¢y.in orderto reflect the dimunilion in the ass8t.a transfer is made from the relevant fixed asset ftjnds to 8ilh8r unreslricl8d or restricted revenue funds, as appropriate to the terms of the original gift, if any. The effect of this policy is that the aggregate of all f￿ed asset funds shall equ8le to the net book value of fixed assets. In the first year that this policy was adopted, a transfer to fixed asset fund8 was made equivalent to th8 n8t book value of the assets. Any residual liability to the donor arising from, for example, the asset's futu￿ sale, is disdosed as a contingent liability unl8SS the event thatWOu￿ trigger r8paymenl of the grant becom88 probable in which ca8e a liability for repaym&nt 18 recognised. Insofar as this policy relat88 to Government gr8nt8 and to the extent that it may ￿ a departur8 from the FRS 102 SORP (Statement of Recommended Practits forA¢¢ounting and Reporting by Charities) 2019. applicable to all a¢¢ounting periods beginning on Dr after 181 January 20191, (The SORPI, 8uch departure is justified on the basis that it is in order to Comply wth the SORP. stocks and work In prog￿$ Stock is valued al the lower of cost and net ￿aliSable value. Debtors Debtors are messured at their recoverable amounts at the balance sheet date. Creditor5 and provisions Liabilitie5 are measured at their setdernenl amount. A liability is iectyni5ed for the the amount the Chaiity anticpates it wll pay to setlle the deb or the amount It has received as an advance payment for goods or servi￿$ It must provide. Financial instrument5 including cash and bank balances Ca8h he￿ by the charity 18 included at the amount actually hek1 and counted al the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts property reconcikd to the bank statements. Fund Aeeounting Unrestri¢ted funds are available for use at the dis¢retion of the trustees in furtheffjn¢e of the general obie¢lives of the charity. There are no endowment funds. 18

Leukaemia & Myeloma Research UK Ltd Notes to the Accounts for the year ended 31 March 2024 2 Liability to tsxation The Trustees consider that the charity sati8fi88 the lesls set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK ¢trrpofylion lax purposes. Accordingly, the Charity is potentially exempt trom taxation in ￿Spect of income or Capital gains received wthin categori88 covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains A¢t 1992. to the extent that such In¢ome or gains a￿ applied exdusively on the spe¢rfi¢ charrtable objects of the charity and for no other purp08&. 3 Winding up or dissolution of tha charity If upon winding up or dissolution of the charity there remain 8ny assets, after the sat18faetion of all debts and liabilities, the assets represented by the accumulated fund shall be Iiansferred to sorne other tharitab￿ body or bodies having similar objects to the charity. 4 Defined ¢ontribution pension $¢heme¥ Any liabilites and a55ets as50cialed with the scheme are shown under debtors and creditors. S Remuneratlon and payments to Trustees and persons connected wlth them The trustee5 reTrwed payments in the amount of £1,082 a5 travel expenses related to providing service5 for dothing 6 Tangible fixed assets Current Year Land and Bulldlngs Plant & Machlnery Motor Vehlcles Total Cost At 1 April 2023 Addition5 4,099 24,570 575 23.￿5 At 31 March 2024 4,674 23,995 28,669 Depre¢latlon At 1 April 2023 Charge for the year 2,275 1.168 2,275 7,167 s.￿9 At 31 March 2024 3,443 5,999 9,442 Net book value At 31 Alarch 2024 1,231 17,996 19,227 At 31 March 2023 1,824 1,824 19

Leukaemia & Myeloma Research UK Ltd Notes to the Accounts for the year ended 31 March 2024 7 Stocks & Work in Progress 2024 2023 Stocks before write downs 27.319 17.490 27.319 17.490 8 Debtors 2024 2023 Trade debtors Prepayments and accrued Income Other debtors 833 280 3,947 294 6.032 12,326 S,060 9 Crèditors= amounts falling due within on* ￿ar 2024 2023 Trade creditors Accruals 3.099 1.080 3.643 1,920 4,179 5,563 10 Partlculars of how partlcular funds are represented by assets and Ilabllltles At 31 Mar¢h 2024 Unr•stri¢tsd fvnd$ D•siynat•d fund8 Rostri¢tsd funds Total Furtd¥ Tangible Fixed Assets cur￿ntAs$ets cur￿ nt Liabilities 19.227 331,88> 14.17gi 19,227 375,156 14,1791 43,467 346,737 43,467 390.204 At 1 April 2023 Unrestricted funds Designated funds Restrictsd funds Total Funds Tangible Fixed Assets CurrentAssets 1.824 315.474 15.5631 1.824 356,060 15.5631 40.586 311,735 40,S86 352,321 20

Leukaemia & Myeloma Research UK Ltd Notes to the Accounts for the year ended 31 March 2024 11 Change in total funds over the year as shown in Note 10 , analysèd by individual funds Funds brought Movèmènt In forward from funds in 2024 2023 Fund$ carrièd forward to ZOZ5 between funds 2024 So0 Noto 12 So0 N¢)ts 13 Unresthctedand deslgn8ted funds... Unrestricted Revenue Funds 311.735 35.002 346.737 Totsl unrestrlcted and deslgnated funds 311,735 35,002 346,737 Restrlcled funds... R8s&arch Model Cell Biobank 1.350 1.531 1,350 42,117 40.586 Total restricted funds 40,586 2,881 43,467 Total charity funds 352,321 37,883 390,204 12 Analysi¥ of movements in funds over the year as shown in Note 11 Other Gains & Losses 2024 Income Exppnditure Movernent in funds 2024 2024 2024 Unre5trictedand design4ted funds... Unrestricted Revenue Funds 308.626 1273.6241 35,002 Restri¢tedfunds.'. Research Model Cell Biobank 39.050 12.855 137,7001 111,1241 1,350 1,531 360,331 1322,4481 37,883 21

Leukaemia & Myeloma Research UK Ltd Notes to the Accounts for the year ended 31 March 2024 13 The purposes for which the funds as detailed in note 11 are held by the charity are'.- Unr05trictedand d8signat8d funds... These funds 8re held for the meeting the objectives of the ch8rty. and to provide reserves for future activities. and , subject to charity kg181alion. are free from all restrictions on their use. Unrestricted Revenue Funds Restri¢tedfunds.'. Research The purpose of these funds is described under tt)e a¢¢ounting policy. The purpose of these fund5 is described under the accounting policy. Model Cell Biobank 14 Ultimate controlling party The charity is under the control of 115 legal members. For compan￿S Itd by guaranl8e- Every member of the charity is obliged lo contribute such amount as may be required to contribute lo the assets of the Company in the event of its being wound up while he or she Is a member. Dr ￿tr)In one year after he or she ceases to be a member.

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 This analysis is classsrfied by conventional nominal descriptions and not by activity. 15 Donations. Grants and Lggacios Currentyear Unrestrlctsd Fund$ Curreni year Restrlcted Funds Currentyear Total Funds Prior Year Totsl 2024 2024 2024 2023 Small donations individually less than £1000 3,297 3,297 8,415 Stripe Direct Donations 13,177 13.177 14,707 Holyhead Church 6,536 Facebook 1,508 1.508 2,523 Just Giving 60,725 60.725 47,846 Kilfvlalk 2,880 In Memory 12,693 12.693 17,856 Muchloved 2,688 2.688 7,859 Giving.com 2,646 Paypal Giving 8,605 8.605 2,895 CAF 3,367 3.367 Total donations and gifts from individual8 106.060 106.060 114.163 Donatlons and glfts from Indlvlduals Ilnclude HMRC refunds on glft alded donatlonsl- Prlor Year analysls Prior Year Unrestrlcted Fund$ Prioryear Restrlcted Funds Prior Year Total Funds 2023 2023 2023 Prior year 114,163 114,163 23

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 CurrÈntyear unresinctea Funds CUr￿n1 year Kestriciea Funds Cur￿￿tyear Total Funds Prior Year Totsl Funds 2024 2024 2024 2023 Lagaeiès rèeaivablè Srnall legacies individualty le5S than £1000 750 7SO Sylvia Allanson 1,500 Malcolrn Squibb 5,000 David C T8yIoi 3,000 3,000 Nick Glynnelmartin Gtynne 5,000 5,000 HolTnes & Hills LLP 44,843 44,843 Jackson Lees Group Ltd 3,750 3,7SO C*heiine Dunne and Raohel O'Mall&l 10,000 10,000 Total l8gaei•$ reeervable 67.343 67.343 6.500 L•9aeiès r•eeivablè- Prior Yèar analysis Prioryear Unresiricted Fund$ Prioryear Restricted Fund$ Prioryear Total Fund$ 2023 2023 2023 Prlor year 6,500 6,500 24

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 CurrÈntyear unresinctea Funds CUr￿n1 year Kestriciea Funds Cur￿￿tyear Total Funds Prior Year Totsl Funds 2024 2024 2024 2023 Revenue grants from govemment and public bodies Srnall grants individu81ty less than £1000 590 2,300 2,890 12,700 Orange Tree Trust 2,500 2,500 Hilary Awdry Tiusl 2,000 2,000 Medicash Trust 3,000 3,000 John Mason Charitsble Trust 3,500 3,500 The Famity Rich Charitie5 Trust 5,000 R*hbone Investrnent Management 3,000 3,000 Mithael Watson Charitable Trust 2,500 2,500 May Nearnshaw Gharitsble Trust 2,000 Ladbrokes Coral Trust 2,500 The Gledswood Charitsble Trust 5,000 Dorothy Homes Charitable Trust 5,000 L & R Gilley Charitable Trust 2,500 2.500 The Sunset Charitable Trust 5,000 5.000 Total public sector revenue grants 7,090 19,800 26,890 32,200 R•v•nu• grants from gov•mmènt and publie bodies - Prior Yèar analysis Prioryear Unrestricted Funds 2023 Prioryear Restricted Fund5 2023 Prioryear Ttstsl Fund$ 2023 Prior Yèar 32,200 32,200 25

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 Currentyear UnrestriGted Funds 2024 Current year Restricted Funds 2024 Currenty8ar Total Funds Prior Year Total Funds 2024 2023 Revenue grants and donations from non public bodies Small grants individualty less than £10(M) 1,397 3,255 4,652 427 Lunya Limited 7,685 Fundraising Support Ltd 2,650 2,650 10,000 Golders Green Foundation 2,000 2,000 Theatrical Society 3,000 Prowting Charitable Foundation 10,000 10,000 Robert Luff Foundation 10,000 10,000 Barratt Development 2,000 2,000 Bognor Regis GO￿ Club 2,767 2,767 CBRE ASD 1,500 1,500 Kwnis London 2,000 2,000 Markeyl International 2,975 2,975 The Hospital Saturday Fund 2,000 2,000 Total prlvate sector revenue grants 10,639 31,905 42,544 21,112 Revenue grants and donatlons from non publlc bo(Iles Ilnclude Glft AS(1 donatoons from subsldlarlesl Prior Year analy515 Prioryear Prioryear Prioryear Unre$iricted Fund$ RÈstricted Fund5 Total Funds 2023 2023 2023 Prior Year 21,112 21,112 26

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 Total Donations, Grants and Legacies Unrestricted Funds Restricted Funds Current Year Total Funds Prioryear Total Funds Currentyear 2024 2024 2024 2023 Total Donations. Grants and Legacies A1 191,132 51,705 242,837 173,975 UnrestriGted Funds 2023 Restricted Fund5 2023 Prioryear Total Funds 2023 Prloryear Total Donations, Grants and Leoaeie$ A1 173.975 173,975 16 Income from charitable activities - Trading Activities Currentyear Currentyear Unrestrfjcted Funds Current year Restrlcted Funds Currentyear Total Funds Prior Year Total funds 2024 2024 2024 2023 Prlmary purpose and anclllary tradlng Sale of goods and services in acctsidance with the Charity's objects 63,177 63,177 20,553 Total Primary purpose and anclllary tradin9 63,177 63,177 20,553 Prioryear Prioryear Unrestricted Funds 2023 Prioryear Restricted Funds 2023 Prioryear Total Funds 2023 Primary purpose and aneillary tradin9 Sale ol goods and services in accordance with the charity's objects 20,553 20.553 Totsl Primary purpose and an¢illary trading 20.553 20,553 27

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 17 Total Income from charitable activities Currentyear UnrestriGted Funds Current year Restricted Fund5 Currentyoar Total Funds Prior Yèar Currentyear Total Funds 2024 2024 2024 2023 Total income from charitable trading 63,177 63.177 20,553 Total from charitable activitie¥ A2 63.177 63.177 20.553 Income from charitable activities - Prior Year analysis Prlor Year UnreslriGted Funds Prlor Year Restricted Funds Prlor Year Prioryèar Total Funds 2023 2023 2023 Total income from ohaiitable trading 20,553 20,553 20.553 20,553 28

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 18 Investment income CurrÈntyÈar unresinctea Funds Current year estrictea Funds CurrÈntyear Total Funds Prior Year Totsl Funds 2024 2024 2024 2023 Bank Interest Re￿1vable 4,317 4,317 665 Total Snvestment Income 4,317 4,317 665 Investment Sncome- Prlor Year analysls Unresiricted Fund$ Restricted Funds T¢>tal Fund$ Prior Year 665 665 19 Other income and gains Currentyear unresinc￿u Funds Curreni year estriciea Funds Currentyear Total Funds Prior Year Total Funds Currentyear 2024 2024 2024 2023 Royalties from the exploitation of intellectual property rights 50,000 50,000 50,063 Total other Sneome A5 50.000 50.000 50.063 Other income and gains - Prior year analysis Prior Year unresincted Fund$ Prior Year Restricted Fund$ Prior Year Total Funds Prior Year 2023 2023 2023 Royalties from the exploitation of intellectual property rights 50,063 50,063 Total other Sncome AS 50,063 SO,063 29

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 20 Expendlture on charltable actlvltles - Dlrect spendlng Currentyear unresirtcted Fund$ Current year Restricied Funds Currenty8ar Total Funds Prior Year Total Funds Current Year 2024 2024 2024 2023 Travel and Subsistence - Charitable Activities Costs of activities and events Consultsncy and professional support Travel and Subsistence - Trustees Travel Expenses 470 470 218 12,207 38,586 8,671 20.878 38.586 36.661 33.333 1,082 1,082 1.292 Total direct spending 82a 52.34S 8,671 61,016 71.504 Prioryear Unrestricted Funds Pritsryear Restricted Funds Prioryear Total Funds Prior Year 2023 2023 2023 Travel and Subsistence - Charitable Activities Costs of activities and events Consultancy and professional support Travel and Subsistence - Trustees 218 218 36,661 33,333 1,292 36,661 33,333 1.292 Total dlrect spendlng B2a 71.504 71.504 30

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 21 Expenditure on charitable activities - Charitable trading Currentyear unresincteu Funds Current year K8strict8a Funds Currentyear Total Funds Prior Year Total Funds Current Year 2024 2024 2024 2023 Cost ofgoods for primary purpose trading - Including movement in stock Cost of Shipping, Freigh and DelThiery 54.307 54,307 7.874 1,894 1,894 Tgtsl ¢haritsble trading ¢o¥ts 82b 56.201 56,201 7.874 Prior Year unresirtcted Funds Prior Year Restriciea Funds Prior Year Total Funds Prior Year 2023 2023 2023 Cost of g(iods for primary purpose trading - Including movement in stock 7,874 7.874 Total charitable trading costs B2b 7,874 7,874 22 Expendlture on charltable actlvltles- Grant fundlng of actlvltles Currentyear Unres¢riGted Funds urrent year Restricted Fund5 Currentyear Total Funds Prior Year Total Funds CU￿ent Year 2024 2024 2024 2023 Grants made lo organisations 19,800 37,700 57.500 25.000 Total grantmaking costs B2c 19,800 37,700 S7,500 25,000 31

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 Breakdown of Grants made to organlsatlons Currentyear unresirtcted Fund$ Current year Restricted Funds Currenty8ar Total Funds Current Year 2024 2024 2024 G8rdiff University Btunel University 35.000 2,700 35,000 22,500 19,800 19,800 37.700 57.500 Prlor Year UnrestriGted Funds Prlor Year Restricted Fund5 PrlorYe8r Total Funds Prior Year 2023 2023 2023 Grants made lo organisations 25,000 25.000 Total grantmaklng costs B2c 25.000 25.000 32

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 23 Support costs for charitable activities Currentyear unresirtcted Funds Current year Restricted Funds Currentyear Total Funds Prior Year Total Funds Current Year 2024 2024 2024 2023 Employee costs not Included In dlreet Costs Sub¢onlraclors 1,328 1,328 Premises Expenses Rates and water charges Room Hire Light heat and power Cleaning and waste management Premises repairs, renewals and maintenance Propety insurance Storage 397 24,607 521 1.427 397 24,607 521 1,427 219 24.212 17 420 420 686 701 2,554 701 2,554 596 Admlnlstratlve overheads Telephone, fax and internet Postage Stationery and printing Membership subscriptions Equipment expenses Hire of equipment Software licences and expenses Advertising and marketing Sundry expenses Motor Expenses 1,921 1,053 1,608 8.568 1,414 1,339 3,968 27,873 2,045 3,867 1.921 1,053 1.608 8,568 1,414 1,339 3.968 30,326 2,045 3,867 2.184 698 1.480 7,895 2,199 1,099 4.098 11,746 2,453 Pmfessional fees paid to advisors other than the audiTtor or examiner Accountsncy fees other than examination or audit fees 240 Management fees Other legal and professional 240 710 32,638 5,121 32,638 5,121 26.745 660 FITnaneiTal costs Bank charges Depreciation & Amortisalion in total for 112 7,167 112 7,167 35 1,025 Support costs before reallocation 130.889 2,453 133.342 86.304 Total support costs- Current Year 130,889 2,453 133,342 86,304 The basis of allocation of cost5 between aotivilies is described under accounting policies All the expenditure in the prior year was unrestricted. 33

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 Prfor Year Unre$¢riGted Funds Prloryear Re5triGte Fund5 PrlorYe8r Total Funds Prior Year 2023 2023 2023 Premises Expenses Rates and water charges Room Hire Light heat and power Premises repairs, renewals and maintenance Property insurance 219 24,212 219 24,212 17 686 686 596 596 Administrative overheads Telephone, fax and internet Postage Stationery and printing Membership subscriptions Equipment expenses Hire of equipment Sofvare licences and expenses Advertising and marketing 2,184 698 1,480 7,895 2,199 1,099 4,098 11,746 2,184 698 1,480 7.895 2.199 1.099 4,098 11,746 Professional fees paid to advisots Accountancy fees other than examination or audit fees Management fees Other legal and professional 710 710 26,745 660 26,745 660 Financial costs Bank charges Depreciation & Amortisalion in total for 35 1,025 35 1.025 Support costs before reallocation 86,304 86,304 Total support costs - Prior Year 86.304 86,304 The basis ol allocation of costs between activities is described under accounting policies 34

Leukaemia & Myeloma Research UK Ltd Detailed analysis of income and expgndituro for the year ended 31 March 2024 as requirod by the SORP 2015 24 Total Charitable expenditure Currentyear unr88iricte Funds Current year Restri¢i8a Funds Currentyear Total Funds Prior Year Total Fund8 Current Year 2024 2024 2024 2023 Total direct spending Total charitable trading costs Total grantmaking costs Total support costs B2a 52,345 56,201 19,800 130,889 8,671 61.016 56,201 57,500 133,342 71.504 7,874 25,000 86.304 B2b B2c B2d 37,700 2,453 Total charitable expenditure B2 259,235 48,824 308,059 190,682 All the expenditure in the prior yearwas unrestrioted. Prioryear unr8siricte Funds Prioryear Restriciea Funds Prioryear Total Funds Prior Year 2023 2023 2023 Total direct spending Total charitable trading costs Total grantmaking costs Total support costs B2a B2b B2c B2d 71,504 7,874 25,000 86,304 71,504 7.874 25,000 86,304 Total charitable 8xpenditurè 82 190.682 190.682 25 Expenditure on raising funds and costs of investment management Currentyear Current year unresincteu K8strici8a Funds Funds Currentyear Total Funds Prior Year Total Funds Current Year 2024 2024 2024 2023 Agent's costs for fundraising Cost of fundraising activities Fundraising trading costs 7,080 6,337 972 7,080 6,337 972 6,450 11,996 654 Total fundraising Costs B1 14.389 14.389 19.100 All the expenditure in the prior year was unrestricted. Prfor Year unrestricted Funds PrlorY8ar Restricted Fund5 Prlor Year Totsl Funds Prior Year 2023 2023 2023 Agent's costs for fundraising Cost of fundraising activities Fundraising trading costs 6.450 11,996 654 6,450 11.996 654 Total fundraSslng costs B1 19,100 19,100 35